↓ Skip to main content

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients

Overview of attention for article published in Drug Design, Development and Therapy, November 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

patent
8 patents

Citations

dimensions_citation
62 Dimensions

Readers on

mendeley
54 Mendeley